This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mulla, H Articles by Killer, H Search for Related Content PubMed PubMed Citation Articles by Mulla, H Articles by Killer, H Social Bookmarking                         What's this?

In vitro evaluation of sedative drug losses during extracorporeal membrane oxygenation

Glenfield Hospital, De Montfort University Centre for Pharmacy Practice Research, Leicester, hussain.mulla{at}glenfield-tr.trent.nhs.uk

G Lawson

Department of Chemistry, De Montfort University, Leicester

C von Anrep

Department of Chemistry, De Montfort University, Leicester

M D Burke

Glenfield Hospital, De Montfort University, Centre for Pharmacy Practice Research, Leicester

D U Upton

Glenfield Hospital, De Montfort University, Centre for Pharmacy Practice Research, Leicester

R K Firmin

Departments of Cardiothoracic Surgery and ECMO, Glenfield Hospital NHS Trust, Leicester

H Killer

Departments of Cardiothoracic Surgery and ECMO, Glenfield Hospital NHS Trust, Leicester

Sedative agents are routinely administered to critically ill patients, both on and off extracorporeal membrane oxygenation (ECMO), to enable patients to be comfortable and facilitate patient management. It has been observed empirically in our paediatric intensive care unit that doses of sedative drugs required to achieve desired levels of sedation in ECMO patients are far greater than those used in non-ECMO patients. These differences could not simply be accounted for by differences in patient types, clinical status or sedation levels. We therefore undertook an in vitro evaluation of drug binding in ECMO circuits.

This study investigated how the polyvinyl chloride (PVC) and silicone rubber components of neonatal ECMO circuits affect drug delivery in patients through drug sorption. Phase 1 investigated drug uptake by the two polymers in static solutions of known concentrations of four commonly used sedative drugs: lorazepam, midazolam, diazepam and propofol. Phase 2 involved the setting up of a complete neonatal ECMO circuit, injecting the drug solutions pre-reservoir at a flow rate of 350 ml/min and collecting samples post-oxygenator for analysis.

Phase 1 results revealed significant uptake of drugs with losses in the range 40-98% and in the order propofol • diazepam • midazolam • lorazepam. Phase 2 results were similar and in the first 40 min of running an ECMO circuit only 10% of propofol passed through the circuit. These results may help to explain observed clinical phenomena and raise important issues regarding drug dosing in ECMO patients.

Perfusion, Vol. 15, No. 1, 21-26 (2000)
DOI: 10.1177/026765910001500104


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				V. Bhatt-Mehta and G. Annich Sedative clearance during extracorporeal membrane oxygenation Perfusion, December 1, 2005; 20(6): 309 - 315. [Abstract] [PDF]

				B. B DeBerry, J. E Lynch, J. M Chernin, J. B Zwischenberger, and D. H Chung A survey for pain and sedation medications in pediatric patients during extracorporeal membrane oxygenation Perfusion, May 1, 2005; 20(3): 139 - 143. [Abstract] [PDF]

				L. Lequier Extracorporeal Life Support in Pediatric and Neonatal Critical Care: A Review J Intensive Care Med, September 1, 2004; 19(5): 243 - 258. [Abstract] [PDF]